Source: Medicines and Medical Devices Safety Authority (NZ) Revision Year: 2022 Publisher: Viatris Ltd, PO Box 11-183, Ellerslie, AUCKLAND www.viatris.co.nz Telephone 0800 168 169
Letrole, 2.5 mg, film coated tablet.
| Pharmaceutical Form |
|---|
|
Dark yellow, capsule shape, film-coated, slightly biconvex tablet, debossed with “LZ 2.5” on one side and “G” on the other. |
Each film coated tablet contains 2.5 mg of letrozole.
Excipient with known effect: Lactose.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Letrozole |
Letrozole is a non-steroidal aromatase inhibitor. It inhibits the aromatase enzyme by competitively binding to the haem of the aromatase cytochrome P450, resulting in a reduction of oestrogen biosynthesis in all tissues where present. |
| List of Excipients |
|---|
|
Letrole 2.5mg tablet core contains: Lactose monohydrate Letrole 2.5mg tablet film coating contains: Hypromellose |
PVC/PVdC/Aluminium blister. Pack size of 30 film-coated tablets.
Viatris Ltd, PO Box 11-183, Ellerslie, AUCKLAND
www.viatris.co.nz
Telephone 0800 168 169
Date of first approval: 1 April 2010
| Drug | Countries | |
|---|---|---|
| LETROLE | Ecuador, New Zealand |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
